![CEimpact Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5e/ae/42/5eae4208-b706-0adc-12fb-75292fc9ea63/mza_14075584767013252581.jpg/100x100bb.jpg)
The Novel RSV Vaccine: Part 2
CEimpact Podcast
English - May 08, 2023 09:00 - 31 minutes - 21.9 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 2 of a two-part series examining new research on the proposed RSV vaccine.
The GameChanger
RSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in pregnant patients may help newborns.
Show Segments
00:00 - Introductions
02:57 - Recap From Part 1
06:45 - Looking at the MATISSE Study
14:17 - The GameChanger: MATISSE Results
22:27 - Connecting to Practice: Barriers to Applying
31:05 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
Reference
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the MATISSE study in relation to RSV vaccines
2. Describe barriers to applying the information in this study to general populations
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-193-H06-P
Initial release date: 05/08/2023
Expiration date: 05/08/2024
Additional CPE details can be found here.